HOOKIPA Pharma Inc. (NASDAQ:HOOK) is reporting third quarter earnings results on Thursday 12th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.43 per share.
For the full year, analysts predict revenues of $ 19.05 million, while looking forward to loss of $ 1.62 per share.
Previous Quarter Performance
HOOKIPA Pharma Inc. outlined loss for the second quarter of $ 0.28 per share, from the revenue of $ 6.68 million. The consensus estimates are loss of $ 0.47 per share from $ 3.49 million in revenue. The bottom line results beat street analysts by $ 0.19 or 40.43 percent, at the same time, top line results outshined analysts by $ 3.19 million or 91.40 percent.
Stock Performance
Shares of HOOKIPA Pharma Inc. traded up $ 0.03 or 0.27 percent on Wednesday, reaching $ 11.09 with volume of 33.50 thousand shares. HOOKIPA Pharma Inc. has traded high as $ 11.13 and has cracked $ 10.69 on the downward trend
The closing price of $ 11.09, representing a 90.69 % increase from the 52 week low of $ 5.80 and a 23.03 % decrease over the 52 week high of $ 14.37.
The company has a market capital of $ 284.51 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 26th October 2020, initiated by JMP Securities at Market Outperform rating, with $ 19.00 target price.
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The companys lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers.
